Gyre Therapeutics (NASDAQ:GYRE) Sets New 1-Year Low – What’s Next?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $6.01 and last traded at $6.04, with a volume of 95332 shares. The stock had previously closed at $6.26.

Analyst Ratings Changes

Several analysts have recently issued reports on GYRE shares. Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings lowered Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Finally, Zacks Research lowered Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Two analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Stock Performance

The company has a fifty day moving average of $7.24 and a two-hundred day moving average of $7.60. The company has a market cap of $588.00 million, a PE ratio of -67.33 and a beta of 2.03.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%. The company had revenue of $37.20 million for the quarter, compared to analysts’ expectations of $36.30 million. On average, equities analysts forecast that Gyre Therapeutics, Inc. will post -0.3 EPS for the current year.

Insiders Place Their Bets

In other Gyre Therapeutics news, CEO Ying Luo sold 10,136 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total value of $81,493.44. Following the sale, the chief executive officer owned 2,565,226 shares in the company, valued at $20,624,417.04. This trade represents a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Weiguo Ye sold 12,820 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $6.15, for a total value of $78,843.00. Following the completion of the sale, the chief operating officer owned 700,000 shares in the company, valued at approximately $4,305,000. The trade was a 1.80% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 32,535 shares of company stock worth $219,580. Insiders own 10.00% of the company’s stock.

Institutional Trading of Gyre Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN increased its stake in Gyre Therapeutics by 132.4% in the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after purchasing an additional 7,361 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Gyre Therapeutics in the fourth quarter worth $77,000. Goldman Sachs Group Inc. increased its stake in Gyre Therapeutics by 72.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 31,108 shares of the company’s stock worth $220,000 after purchasing an additional 13,074 shares during the period. Alliancebernstein L.P. increased its stake in Gyre Therapeutics by 9.5% in the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock worth $163,000 after purchasing an additional 1,900 shares during the period. Finally, Lazard Asset Management LLC purchased a new stake in Gyre Therapeutics in the third quarter worth $111,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.